BTRC and cancer: SOX9 overexpression leads to the inhibition of T-cell factor (TCF)-binding activity and suppression of β-transducin repeat–containing protein (β-TrCP)-mediated protein degradation, promoting nuclear expression of glioma-associated oncogene homolog 1 (GLI1), resulting in enhancement of cancer stem cell properties [24].